Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effect of E-Health Management on Gestational Diabetes Control

30 de octubre de 2018 actualizado por: Mei-Chen Su, Chang Gung Memorial Hospital

Randomized Controlled Trail of e-Health Management for Women With Prior Gestational Diabetes Mellitus

The purpose of this study was to develop an e-heath management platform(eHMP) for women with high risk of gestational diabetes mellitus (GDM) and to evaluate the longitudinal effects between groups of eHMP intervention.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

Background: Women with previous gestational diabetes mellitus are at increased risk for developing type2 diabetes mellitus or metabolic syndrome in their later life. Infants of mothers with GDM are more susceptible to stillbirth and more serious health concerns. With limited time for visits and the predicament of education, applying web-based intervention has become a convenient tool for health management.

Objectives: The approved project aimed to develop an e-heath management platform(eHMP) for women with high risk of gestational diabetes mellitus (GDM) and to evaluate the longitudinal effects between groups of eHMP intervention. The eHMP integrate GDM health care knowledge, self-awareness of health, self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends); participation in discussions or browsing forums; healthy lifestyle guidance and counseling; reminder systems, a token system of earning points in exchange for prizes.

Methods: Pregnant women aged 18-45 years with high risk of metabolic syndrome who have a singleton pregnancy, are eligible to participate in this study. Women who agree to participate in the study will be given a participant information sheet and consent form. Participants will be recruited from the Pregnancy diabetes Clinic, at Chang Gung memorial hospital and introduced to the eHMP using the mobile phone in the clinic. Participants will also be given the URL to access to the program and they can learn the modules at home by using their home PCs, mobile phones, or tablets. They were followed up for three times: 28 weeks' gestation, 36-40 weeks' gestation and 6-12 weeks postpartum. SPSS version 20.0 software was used to compile and analyze the research data, including questionnaires and blood test for metabolic index.

Tipo de estudio

Intervencionista

Inscripción (Actual)

112

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Taipei, Taiwán, 10507
        • Chang Gung Memorail Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 45 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

Pregnant women (pre-pregnancy body mass index ≧ 24) must meet at least one of the following conditions and agree to be interviewed:

  • Age over 34 years old;
  • Ever had giant infant delivery (weight ≧ 4.5 kg);
  • Previous diagnosed with gestational diabetes ;
  • Family history of diabetes.

Exclusion Criteria:

  • Pre-existing diabetes (types 1 and 2);
  • Unable to write and understand Chinese;
  • Subject has cognitive impairment;
  • Subject has intellectual disability or mental illness;
  • Dependent on medical care (eg, anti-depressants, or any psychiatric medication)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: eHMP experimental group

The experimental group received health management support and counseling,including:

  1. GDM health care knowledge
  2. self-awareness of health
  3. self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)
  4. participation in discussions or browsing forums
  5. healthy lifestyle guidance and counseling
  6. reminder systems
  7. a token system of earning points in exchange for prizes.
Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Otros nombres:
  • e-Health Management Platform
Sin intervención: Control group
only received usual care

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change of Triglyceride Level
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Blood sampling was performed in the fasting state. Normal triglyceride was <150 mg/dl; ≥150mg/dl was abnormal
Change from Baseline at 6-12 weeks after delivery
Change of Fasting Blood Glucose (FBG) Level
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Blood sampling was performed in the fasting state. Normal FBG was < 100 mg/dl; ≥100mg/dl was abnormal
Change from Baseline at 6-12 weeks after delivery
Change of high-density lipoprotein cholesterol (HDL) level
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Blood sampling was performed in the fasting state. Normal HDL was ≥50 mg/dl; <50mg/dl was abnormal
Change from Baseline at 6-12 weeks after delivery
Change of Cholesterol level
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Blood sampling was performed in the fasting state. Normal Cholesterol was < 200 mg/dl; ≥200mg/dl was abnormal
Change from Baseline at 6-12 weeks after delivery
Change of systolic blood pressure
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Normal systolic blood pressure was <130mmHg; ≥130mmHg was abnormal. Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
Change from Baseline at 6-12 weeks after delivery
Change of diastolic blood pressure
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Normal diastolic blood pressure was <85mmHg; ≥85mmHg was abnormal. Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
Change from Baseline at 6-12 weeks after delivery
Change of body weight
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
Women's weight following as assessed using calibrated digital scales
Change from Baseline at 6-12 weeks after delivery
Newborn baby weight
Periodo de tiempo: at birth
Newborn baby weight in normal range (>2500g - <4500g) - dichotomous outcome Yes/No assessed using calibrated digital scales.
at birth

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change of Pregnancy Physical Activity Assessment
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
There are 12 items in this questionnaire, including two dimensions: exercise and inactivity. Exercise dimension contained four items to assess the type of physical activity, intensity, duration, frequency during pregnancy. At least 3 days per week, and each time at least 20-30 minutes, counted as regular exercise (dichotomous outcome Yes/No assessed). Inactivity dimension contained 8 items, dichotomous outcome Yes/No assessed (score 0-8), higher values represent an inactivity lifestyle.
Change from Baseline at 6-12 weeks after delivery
Change of Dietary Behavioral Characteristics Scale
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
The instrument is 17-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always). It including two dimensions and each scale range as: balanced diet (5 items, scale range 5-25) and diet control behavior (12 items, scale range 12-60). Higher values represent a better maternal dietary patterns during pregnancy.
Change from Baseline at 6-12 weeks after delivery
Change of Health Promotion Scale
Periodo de tiempo: Change from Baseline at 6-12 weeks after delivery
The instrument is 40-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always). It including six dimensions and each scale range as: social-support (6 items, scale range 6-30), life-appreciation (8 items, scale range 8-40), health-responsibility (8 items, scale range 8-40), stress-management (9 items, scale range 9-45), nutritional behaviors (5 items, scale range 5-25) and exercise behaviors (4 items, scale range 4-20). The total score was 40 to 200, higher values represent a better health promotion lifestyle.
Change from Baseline at 6-12 weeks after delivery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Mei-Chen Su, Dr., Chang Gung Memorial Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de enero de 2017

Finalización primaria (Actual)

28 de febrero de 2018

Finalización del estudio (Actual)

28 de febrero de 2018

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2018

Primero enviado que cumplió con los criterios de control de calidad

30 de octubre de 2018

Publicado por primera vez (Actual)

1 de noviembre de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de noviembre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2018

Última verificación

1 de octubre de 2018

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir